Success Metrics

Active Trials
4(67%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
3
50%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting3
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting117%
not_yet_recruiting233%
recruiting350%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06651229
active_not_recruitingphase_1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903
recruitingphase_3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222
not_yet_recruitingphase_2

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

NCT07264010
not_yet_recruitingphase_2

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

NCT07052422
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06651229Phase 1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Recruiting
NCT05453903Phase 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Active Not Recruiting
NCT06852222Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting
NCT07264010Phase 2

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Not Yet Recruiting
NCT07052422Phase 2

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not Yet Recruiting
NCT06696183Phase 2

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6